BMEA (Biomea Fusion) Beta: 1.2900 (As of Jun. 26, 2026)


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.23
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Beta?

Biomea Fusion BMEA -1.60% 31 Beta is 1.2900 as of Jun. 26, 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Biomea Fusion's Beta is 1.2900.


Biomea Fusion  (NAS:BMEA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Biomea Fusion Beta Related Terms


Biomea Fusion Beta Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion Beta Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.22 2.49

Biomea Fusion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 1.19 1.63 2.49 1.36

BMEA vs VRCA, PMN, SEER: Beta Comparison

For the Biotechnology subindustry, Biomea Fusion's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Beta distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Beta falls into.


BMEA
31GF Score
Biomea Fusion Inc BMEA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.2900 mean?
Biomea Fusion (BMEA) has a Beta of 1.2900 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Biomea Fusion and its competitors.
Is Biomea Fusion's Beta too high?
Biomea Fusion's current Beta is 1.2900. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Beta compare to VRCA and PMN?
Biomea Fusion's Beta of 1.2900 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Biomea Fusion and its competitors. Biomea Fusion's current Beta is 1.2900. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Beta of 1.2900. The current Beta is 1.2900. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Beta is 1.2900 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.23
Price